We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neratinib HER Mutation Basket Study (SUMMIT) (SUMMIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01953926
Recruitment Status : Recruiting
First Posted : October 1, 2013
Last Update Posted : January 18, 2018
Sponsor:
Information provided by (Responsible Party):
Puma Biotechnology, Inc.

Brief Summary:
This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Neratinib Drug: Paclitaxel Drug: Fulvestrant Drug: Trastuzumab Phase 2

Detailed Description:

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification.

The trial will consist of a screening period, a treatment period, and an end of treatment visit occurring when neratinib is discontinued for any reason, a safety follow-up visit occurring 28 to 42 days after the last dose of neratinib and a survival follow-up period lasting for a maximum of 12 months for each patient after their last dose of neratinib or until initiation of additional anti-cancer therapy.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 392 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION
Actual Study Start Date : September 30, 2013
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Neratinib
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Neratinib monotherapy
Neratinib monotherapy in any HER2 mutated cancers excluding colon cancer, lung cancer, breast cancer and bladder cancer. Neratinib monotherapy in any HER4 mutated cancer and in lung cancer containing EGFR exon 18 mutations.
Drug: Neratinib
240 mg administered orally, once daily with food, continuously in 28 day cycles
Other Name: Nerlynx
Experimental: Neratinib and Paclitaxel
Neratinib and Paclitaxel in HER2 mutated bladder cancers.
Drug: Neratinib
240 mg administered orally, once daily with food, continuously in 28 day cycles
Other Name: Nerlynx
Drug: Paclitaxel
80mg/m^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
Experimental: Neratinib, Fulvestrant and Trastuzumab
Neratinib, Fulvestrant and Trastuzumab in HER2 mutated hormone positive breast cancers.
Drug: Neratinib
240 mg administered orally, once daily with food, continuously in 28 day cycles
Other Name: Nerlynx
Drug: Fulvestrant
500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
Experimental: Neratinib and Trastuzumab
Neratinib and Trastuzumab in ERBB2 mutated Hormone negative breast, lung, and colorectal cancers.
Drug: Neratinib
240 mg administered orally, once daily with food, continuously in 28 day cycles
Other Name: Nerlynx
Drug: Trastuzumab
Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter



Primary Outcome Measures :
  1. Objective Response Rate (ORR first) [ Time Frame: 8 weeks ]
    Confirmed objective response rate following treatment with neratinib in patients with HER2 (ERBB2), HER3 (ERBB3) or EGFR mutation-positive solid tumors or with EGFR gene amplification.


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Estimated 6 months ]
    Confirmed objective response rate (ORR) according to RECIST v1.1 or other defined response criteria with neratinib monotherapy and combination therapy.

  2. Progression-free survival (PFS) [ Time Frame: Estimated 18 months ]
  3. Clinical Benefit Rate (CBR) [ Time Frame: 16 weeks ]
    Percentage of patients with complete response (CR) + partial response (PR) + stable disease (SD) ≥16 weeks from the date of enrollment

  4. Duration of Response (DOR) [ Time Frame: Estimated 1 year ]
    Time from which measurement criteria are met for overall response of CR or PR (whichever status is recorded first) until the first date of documented disease progression.

  5. Overall Survival (OS) [ Time Frame: Estimated 2 years ]
    Time from Cycle 1 Day 1 to death due to any cause.

  6. Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs]) [ Time Frame: From consent through 28 days following treatment completion (estimated 6 months) ]
    Safety profile and tolerability of neratinib monotherapy and combination therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed cancers for which no curative therapy exists.
  • Documented HER2 mutation.

Exclusion Criteria:

  • Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib, neratinib).
  • Patients who are receiving any other anticancer agents.
  • Symptomatic or unstable brain metastases.
  • Women who are pregnant or breast-feeding.

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01953926


Contacts
Contact: Puma Biotechnology Clinical Operations Senior Director (424) 248-6500 ClinicalTrials@pumabiotechnology.com

  Show 32 Study Locations
Sponsors and Collaborators
Puma Biotechnology, Inc.
Investigators
Study Director: Clinical Development Senior Vice President Puma Biotechnology, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Puma Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT01953926     History of Changes
Other Study ID Numbers: PUMA-NER-5201
2013-002872-42 ( EudraCT Number )
First Posted: October 1, 2013    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Puma Biotechnology, Inc.:
Neratinib
Nerlynx
Breast
Gastroesophageal
Endometrial
Ovarian
Biliary Tract
Solid Tumors
Cancer
HER2
HER4
EGFR
Bladder/Urinary Tract
Paclitaxel
Fulvestrant
Trastuzumab

Additional relevant MeSH terms:
Paclitaxel
Fulvestrant
Albumin-Bound Paclitaxel
Trastuzumab
Estradiol
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogens
Hormones